Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2017
At a glance
- Drugs Nivolumab (Primary) ; Veliparib (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours; T cell lymphoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
- 01 Jun 2017 Status changed from not yet recruiting to recruiting.